Clinical Trial Update: A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BFB759 in adults with moderate to severe atopic dermatitis is currently recruiting. The sponsor is Bluefin Biomedicine, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BFB759

Snippet

Sponsor: Bluefin Biomedicine, Inc. | Conditions: Atopic Dermatitis (AD) | Phase 2 | Status: RECRUITING